{
    "nct_id": "NCT04269213",
    "official_title": "A Phase II Study of CPX-351 in Younger Patients &lt; 60 Years Old With Secondary Acute Myeloid Leukemia",
    "inclusion_criteria": "* Newly diagnosed:\n\n  * Therapy-related acute myeloid leukemia (AML)\n  * AML with antecedent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)\n  * AML with MDS-related changes (as per World Health Organization [WHO])\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n* Plasma creatinine =< 1.5 x upper limit of normal (ULN)\n* Total bilirubin < 2.0 mg/dL\n* Serum alanine aminotransferase and aspartate aminotransferase < 3 x ULN\n* Left ventricular ejection fraction by echocardiogram or multiple-gated acquisition >= 50%\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment and commit to two forms of birth control\n* Men must use a latex condom during any sexual contact with women of childbearing potential\n* Willing to adhere to protocol specific requirements\n* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 59 Years",
    "exclusion_criteria": "* Prior treatment of AML\n* Known clinically active central nervous system (CNS) leukemia\n* Core-binding factor leukemia\n* Acute promyelocytic leukemia\n* Uncontrolled other malignancy\n* Prior anthracycline exposure > 368 mg/m^2 of daunorubicin or equivalent\n* Cardiovascular disease resulting in heart failure (New York Heart Association class III or IV), unstable angina (angina symptoms at rest), or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months\n* Hypersensitivity to cytarabine, daunorubicin, or liposomal drugs\n* Known active HIV infection\n* Known history of active hepatitis B or C infection\n* Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)\n* Evidence of ongoing, uncontrolled systemic infection\n* Pregnant or breastfeeding women\n* Subject with concurrent severe and/or uncontrolled medical or psychiatric conditions that in the opinion of the investigator may impair the participation in the study or the evaluation of safety and/or efficacy\n* History of Wilson disease or other copper-handling disorders\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",
    "miscellaneous_criteria": ""
}